Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloablative or nonmyeloablative allogeneic hematopoietic cell transplantation

Similar Overall Survival Using Sibling, Unrelated Donor, and Cord Blood Grafts after Reduced-Intensity Conditioning for Older Patients with Acute Myelogenous Leukemia

(2013) Régis Peffault de Latour et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

How I assess comorbidities before hematopoietic cell transplantation

(2013) M. L. Sorror   BLOOD

Significance of minimal residual disease before myeloablative allogeneic hematopoietic cell transplantation for AML in first and second complete remission

(2013) R. B. Walter et al.   BLOOD

Achieving stringent CR is essential before reduced-intensity conditioning allogeneic hematopoietic cell transplantation in AML

(2013) C Ustun et al.   BONE MARROW TRANSPLANTATION

Long-term survival after allogeneic haematopoietic cell transplantation for AML in remission: single-centre results after TBI-based myeloablative and non-myeloablative conditioning

(2013) H Sengeløv et al.   BONE MARROW TRANSPLANTATION

Long-term survival with low toxicity after allogeneic transplantation for acute myeloid leukaemia and myelodysplasia using non-myeloablative conditioning without T cell depletion

(2013) Jeff K. Davies et al.   BRITISH JOURNAL OF HAEMATOLOGY

Detectable minimal residual disease before hematopoietic cell transplantation is prognostic but does not preclude cure for children with very-high-risk leukemia

(2012) W. Leung et al.   BLOOD

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with

(2012) R Martino et al.   BONE MARROW TRANSPLANTATION

Prognostic and therapeutic implications of minimal residual disease at the time of transplantation in acute leukemia

(2012) S A Buckley et al.   BONE MARROW TRANSPLANTATION

Impact of graft-versus-host disease after reduced-intensity conditioning allogeneic stem cell transplantation for acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European group for blood and marrow transplantation

(2012) F Baron et al.   LEUKEMIA

The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: an integrated-risk adapted approach

(2012) Jan J. Cornelissen et al.   Nature Reviews Clinical Oncology

Concise Review: The Role of Hematopoietic Stem Cell Transplantation in the Treatment of Acute Myeloid Leukemia

(2012) Betty K. Hamilton et al.   STEM CELLS

High success rate of hematopoietic cell transplantation regardless of donor source in children with very high-risk leukemia

(2011) W. Leung et al.   BLOOD

Prognostic impact of discordant results from cytogenetics and flow cytometry in patients with acute myeloid leukemia undergoing hematopoietic cell transplantation

(2011) Min Fang et al.   CANCER

Impact of Pretransplantation Minimal Residual Disease, As Detected by Multiparametric Flow Cytometry, on Outcome of Myeloablative Hematopoietic Cell Transplantation for Acute Myeloid Leukemia

(2011) Roland B. Walter et al.   JOURNAL OF CLINICAL ONCOLOGY

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

(2010) D. Grimwade et al.   BLOOD

Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia

(2010) R P Nelson et al.   BONE MARROW TRANSPLANTATION

Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation in Patients With Acute Myeloid Leukemia

(2010) Boglarka Gyurkocza et al.   JOURNAL OF CLINICAL ONCOLOGY

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

HighWT1gene expression before haematopoietic stem cell transplant in children with acute myeloid leukaemia predicts poor event-free survival

(2009) David A. Jacobsohn et al.   BRITISH JOURNAL OF HAEMATOLOGY

Toward Optimization of Postremission Therapy for Residual Disease–Positive Patients With Acute Myeloid Leukemia

(2008) Luca Maurillo et al.   JOURNAL OF CLINICAL ONCOLOGY